Equillium (EQ) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Equillium (EQ) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 2.0% versus a loss of 30.3%. Equillium is the larger company by market cap ($91.3 million vs $84.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | TELO |
|---|---|---|
| Share price | $1.44 | $1.15 |
| Market cap | $91.31M | $84.66M |
| 1-day change | +3.60% | +2.68% |
| YTD return | -7.10% | -13.53% |
| 1-year return | -2.04% | -30.30% |
| 5-year return | -75.63% | — |
| EPS (TTM) | $-0.14 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $1.82 |
| 52-week low | $0.76 | $0.888 |
| Distance from 52-week high | -59.32% | -36.71% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +494.44% | +247.83% |
| Average volume | 583.72K | 97.98K |
| Shares outstanding | 63.41M | 73.62M |
| Employees | 14 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed TELO by 28.3 percentage points over the past year.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Healthcare · Biotechnology · 14 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Healthcare · Biotechnology
EQ vs TELO FAQ
Which is bigger, Equillium or Telomir Pharmaceuticals?
Equillium (EQ) is larger, with a market capitalization of $91.31M compared with $84.66M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, EQ or TELO?
EQ returned -2.04% over the past 12 months, compared with -30.30% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Equillium and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.